Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 8/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24603026 | 0.92 | SUV39H2 (0.45) | NTSR1INSRDPP4SUV39H2IGF1R | |
| SCHEMBL14240636 | 0.89 | NTSR1 (0.47) | NTSR1INSRKDRAXLDPP4 | |
| SCHEMBL520746 | 0.89 | NTSR1 (0.47) | NTSR1INSRKDRAXLDPP4 | |
| SCHEMBL1911870 | 0.85 | DPP4 (0.49) | NTSR1INSRKDRAXLDPP4 | |
| SCHEMBL13849340 | 0.85 | DPP4 (0.49) | NTSR1INSRKDRAXLDPP4 | |
| SCHEMBL29276789 | 0.84 | KDR (0.43) | NTSR1INSRKDRAXLPDGFRB | |
| SCHEMBL29276828 | 0.84 | KDR (0.43) | NTSR1INSRKDRAXLPDGFRB | |
| SCHEMBL29276792 | 0.84 | KDR (0.43) | NTSR1INSRKDRAXLPDGFRB | |
| SCHEMBL12564068 | 0.82 | DPP4 (0.49) | NTSR1INSRKDRAXLDPP4 | |
| SCHEMBL12564521 | 0.82 | DPP4 (0.49) | NTSR1INSRKDRAXLDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | NTSR1 1274/4885INSR 2268/4885KDR 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.